Oral butyrate for mildly to moderately active Crohn's disease

A. Di Sabatino, R. Morera, R. Ciccocioppo, P. Cazzola, S. Gotti, F. P. Tinozzi, S. Tinozzi, G. R. Corazza

Research output: Contribution to journalArticle

98 Citations (Scopus)

Abstract

Background: Butyrate exerts anti-inflammatory effects in experimental colitis and on Crohn's disease lamina propria mononuclear cells in vitro. Aim: To explore the efficacy and safety of oral butyrate in Crohn's disease. Methods: Thirteen patients with mild-moderate ileocolonic Crohn's disease received 4 g/day butyrate as enteric-coated tablets for 8 weeks. Full colonoscopy and ileoscopy were performed before and after treatment. Endoscopical and histological score, laboratory data, Crohn's disease activity index and mucosal interleukin (IL)-1β, IL-6, IL-12, interferon-γ, tumour necrosis factor-α and nuclear factor-kappa B (NF-κB) were assessed before and after treatment. Results: One patient withdrew from the study, and three patients did not experience clinical improvement. Among the nine patients (69%) who responded to treatment, seven (53%) achieved remission and two had a partial response. Endoscopical and histological score significantly improved after treatment at ileocaecal level (P <0.05). Leucocyte blood count, erythrocyte sedimentation rate and mucosal levels of NF-κB and IL-1β significantly decreased after treatment (P <0.05). Conclusions: Oral butyrate is safe and well tolerated, and may be effective in inducing clinical improvement/remission in Crohn's disease. These data indicate the need for a large investigation to extend the present findings, and suggest that butyrate may exert its action through downregulation of NF-κB and IL-1β.

Original languageEnglish
Pages (from-to)789-794
Number of pages6
JournalAlimentary Pharmacology and Therapeutics
Volume22
Issue number9
DOIs
Publication statusPublished - Nov 1 2005

Fingerprint

Butyrates
Crohn Disease
NF-kappa B
Interleukin-1
Enteric-Coated Tablets
Therapeutics
Blood Sedimentation
Colitis
Colonoscopy
Interleukin-12
Leukocyte Count
Interferons
Interleukin-6
Mucous Membrane
Anti-Inflammatory Agents
Down-Regulation
Tumor Necrosis Factor-alpha
Safety

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Oral butyrate for mildly to moderately active Crohn's disease. / Di Sabatino, A.; Morera, R.; Ciccocioppo, R.; Cazzola, P.; Gotti, S.; Tinozzi, F. P.; Tinozzi, S.; Corazza, G. R.

In: Alimentary Pharmacology and Therapeutics, Vol. 22, No. 9, 01.11.2005, p. 789-794.

Research output: Contribution to journalArticle

@article{16323ee8388444f9a180ad604e9c754e,
title = "Oral butyrate for mildly to moderately active Crohn's disease",
abstract = "Background: Butyrate exerts anti-inflammatory effects in experimental colitis and on Crohn's disease lamina propria mononuclear cells in vitro. Aim: To explore the efficacy and safety of oral butyrate in Crohn's disease. Methods: Thirteen patients with mild-moderate ileocolonic Crohn's disease received 4 g/day butyrate as enteric-coated tablets for 8 weeks. Full colonoscopy and ileoscopy were performed before and after treatment. Endoscopical and histological score, laboratory data, Crohn's disease activity index and mucosal interleukin (IL)-1β, IL-6, IL-12, interferon-γ, tumour necrosis factor-α and nuclear factor-kappa B (NF-κB) were assessed before and after treatment. Results: One patient withdrew from the study, and three patients did not experience clinical improvement. Among the nine patients (69{\%}) who responded to treatment, seven (53{\%}) achieved remission and two had a partial response. Endoscopical and histological score significantly improved after treatment at ileocaecal level (P <0.05). Leucocyte blood count, erythrocyte sedimentation rate and mucosal levels of NF-κB and IL-1β significantly decreased after treatment (P <0.05). Conclusions: Oral butyrate is safe and well tolerated, and may be effective in inducing clinical improvement/remission in Crohn's disease. These data indicate the need for a large investigation to extend the present findings, and suggest that butyrate may exert its action through downregulation of NF-κB and IL-1β.",
author = "{Di Sabatino}, A. and R. Morera and R. Ciccocioppo and P. Cazzola and S. Gotti and Tinozzi, {F. P.} and S. Tinozzi and Corazza, {G. R.}",
year = "2005",
month = "11",
day = "1",
doi = "10.1111/j.1365-2036.2005.02639.x",
language = "English",
volume = "22",
pages = "789--794",
journal = "Alimentary Pharmacology and Therapeutics",
issn = "0269-2813",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "9",

}

TY - JOUR

T1 - Oral butyrate for mildly to moderately active Crohn's disease

AU - Di Sabatino, A.

AU - Morera, R.

AU - Ciccocioppo, R.

AU - Cazzola, P.

AU - Gotti, S.

AU - Tinozzi, F. P.

AU - Tinozzi, S.

AU - Corazza, G. R.

PY - 2005/11/1

Y1 - 2005/11/1

N2 - Background: Butyrate exerts anti-inflammatory effects in experimental colitis and on Crohn's disease lamina propria mononuclear cells in vitro. Aim: To explore the efficacy and safety of oral butyrate in Crohn's disease. Methods: Thirteen patients with mild-moderate ileocolonic Crohn's disease received 4 g/day butyrate as enteric-coated tablets for 8 weeks. Full colonoscopy and ileoscopy were performed before and after treatment. Endoscopical and histological score, laboratory data, Crohn's disease activity index and mucosal interleukin (IL)-1β, IL-6, IL-12, interferon-γ, tumour necrosis factor-α and nuclear factor-kappa B (NF-κB) were assessed before and after treatment. Results: One patient withdrew from the study, and three patients did not experience clinical improvement. Among the nine patients (69%) who responded to treatment, seven (53%) achieved remission and two had a partial response. Endoscopical and histological score significantly improved after treatment at ileocaecal level (P <0.05). Leucocyte blood count, erythrocyte sedimentation rate and mucosal levels of NF-κB and IL-1β significantly decreased after treatment (P <0.05). Conclusions: Oral butyrate is safe and well tolerated, and may be effective in inducing clinical improvement/remission in Crohn's disease. These data indicate the need for a large investigation to extend the present findings, and suggest that butyrate may exert its action through downregulation of NF-κB and IL-1β.

AB - Background: Butyrate exerts anti-inflammatory effects in experimental colitis and on Crohn's disease lamina propria mononuclear cells in vitro. Aim: To explore the efficacy and safety of oral butyrate in Crohn's disease. Methods: Thirteen patients with mild-moderate ileocolonic Crohn's disease received 4 g/day butyrate as enteric-coated tablets for 8 weeks. Full colonoscopy and ileoscopy were performed before and after treatment. Endoscopical and histological score, laboratory data, Crohn's disease activity index and mucosal interleukin (IL)-1β, IL-6, IL-12, interferon-γ, tumour necrosis factor-α and nuclear factor-kappa B (NF-κB) were assessed before and after treatment. Results: One patient withdrew from the study, and three patients did not experience clinical improvement. Among the nine patients (69%) who responded to treatment, seven (53%) achieved remission and two had a partial response. Endoscopical and histological score significantly improved after treatment at ileocaecal level (P <0.05). Leucocyte blood count, erythrocyte sedimentation rate and mucosal levels of NF-κB and IL-1β significantly decreased after treatment (P <0.05). Conclusions: Oral butyrate is safe and well tolerated, and may be effective in inducing clinical improvement/remission in Crohn's disease. These data indicate the need for a large investigation to extend the present findings, and suggest that butyrate may exert its action through downregulation of NF-κB and IL-1β.

UR - http://www.scopus.com/inward/record.url?scp=27644432597&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27644432597&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2036.2005.02639.x

DO - 10.1111/j.1365-2036.2005.02639.x

M3 - Article

VL - 22

SP - 789

EP - 794

JO - Alimentary Pharmacology and Therapeutics

JF - Alimentary Pharmacology and Therapeutics

SN - 0269-2813

IS - 9

ER -